A firm has spent $100m on R&D to develop a vaccine against the 2003 SARS virus and the 2012 MERS virus, without success. It is now using some of the results from that research program to develop a vaccine for Covid-19. Should the previous R&D costs be accounted for in the cash flow calculations for the new program? Select one: O A. No. This is a sunk cost as the previous program precedes the decision to look for a Covid vaccine. B. Yes. Since the new program is using some of the old results, a proportionate share of the costs should be allocated to the new program. C. Yes. Since the new program is using some of the old results, the full costs of the old program should be allocated to the new program. D. No. There is no opportunity cost here as the new program does not prevent any other program from using the same results in the future